177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Jakob Stenman, MD PhD
- Número de teléfono: 46 (0)51770000
- Correo electrónico: jakob.stenman@regionstockholm.se
Copia de seguridad de contactos de estudio
- Nombre: Kleopatra Georgantzi, MD
- Número de teléfono: 46 (0)51770000
- Correo electrónico: kleopatra.georgantzi@regionstockholm.se
Ubicaciones de estudio
-
-
Copenhagen
-
Copenhagen, Copenhagen, Dinamarca, DK-2100
- Reclutamiento
- Rigshospitalet
-
Contacto:
- Jesper S Brok, MD PhD
- Correo electrónico: jesper.sune.brok@regionh.dk
-
Investigador principal:
- Jesper S Brok, MD PhD
-
-
-
-
-
Barcelona, España
- Reclutamiento
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
-
Contacto:
- Maite Gorostegui Obanos, MD
- Número de teléfono: +34 93 280 40 00
- Correo electrónico: maite.gorostegui@sjd.es
-
Investigador principal:
- Maite Gorostegui Obanos, MD
-
-
-
-
Vilnius County
-
Vilnius, Vilnius County, Lituania, LT-08406
- Reclutamiento
- Vilnius University Hospital
-
Contacto:
- Jelena Rascon, MD PhD
- Correo electrónico: jelena.rascon@gmail.com
-
Investigador principal:
- Jelena Rascon, MD PhD
-
-
-
-
Oslo
-
Oslo, Oslo, Noruega, NO-0372
- Reclutamiento
- Oslo University Hospital, Rikshospitalet
-
Contacto:
- Kirsten Brunsvig Jarvis, MD
- Correo electrónico: kirjar@ous-hf.no
-
Investigador principal:
- Kirsten Brunsvig Jarvis, MD
-
-
-
-
Utrecht
-
Utrecht, Utrecht, Países Bajos, NL-3584
- Reclutamiento
- Princess Maxima Center for Pediatric Oncology
-
Contacto:
- Max M van Noesel, MD PhD
- Correo electrónico: M.M.vanNoesel@prinsesmaximacentrum.nl
-
Investigador principal:
- Max M van Noesel, MD PhD
-
-
-
-
-
Glasgow, Reino Unido, G51 4TF
- Reclutamiento
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
-
Contacto:
- Diana Mcintosh, Consultant Paediatric Oncologi
- Correo electrónico: Diana.Mcintosh2@nhs.scot
-
Investigador principal:
- Diana Mcintosh, MD
-
London, Reino Unido, NW1 2PG
- Reclutamiento
- University College London Hospitals NHS FOUNDATION TRUST
-
Contacto:
- Jenny Gains, Consultant in Clinical Oncolog
- Número de teléfono: +44-203 447 4437
- Correo electrónico: jenny.gains@nhs.net
-
Investigador principal:
- Jenny Gains, MD
-
London, Reino Unido, SW3 6JJ
- Reclutamiento
- The Royal Marsden NHS Foundation Trust of Fulham Road
-
Contacto:
- Sucheta Vaidya, Paediatric Oncologist
- Correo electrónico: Sucheta.Vaidya@rmh.nhs.uk
-
Investigador principal:
- Sucheta Vaidya, MD
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Suecia, SE-171 76
- Reclutamiento
- Karolinska University Hospital
-
Investigador principal:
- Kleopatra Georgantzi, MD
-
Contacto:
- Kleopatra Georgantzi, MD
- Correo electrónico: kleopatra.georgantzi@regionstockholm.se
-
Contacto:
- Jakob Stenman, MD PhD
- Correo electrónico: jakob.stenman@regionstockholm.se
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
- Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
- Age >18 months at the time of enrolment into this study
- Life expectancy of greater than 3 months
- Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
- Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
- Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
- Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
- Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
- Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures
Exclusion Criteria:
- Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
- Pregnant or lactating patient
- Concurrent treatment with any anti-tumor agents
- Prior treatment with other radiolabeled somatostatin analogues
- Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
- Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
- Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: 177Lu-DOTATATE
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks. |
A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
Periodo de tiempo: 1 months following end of treatment
|
Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC) |
1 months following end of treatment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
Periodo de tiempo: 1 and 4 months following end of treatment
|
Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
Periodo de tiempo: 1 and 4 months following end of treatment
|
Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response by the Revised INRC criteria at 4 months after the completion of therapy
Periodo de tiempo: 4 months following end of treatment
|
Response by the Revised INRC criteria |
4 months following end of treatment
|
|
Progression-free survival
Periodo de tiempo: Time from registration to progression or death, up to 5 years following end of treatment
|
Time to progress or death, whichever occurs first |
Time from registration to progression or death, up to 5 years following end of treatment
|
|
Overall survival - up to 5 years after End of Treatment
Periodo de tiempo: Time from registration to the the date of death, up to 5 years following end of treatment
|
Overall survival |
Time from registration to the the date of death, up to 5 years following end of treatment
|
|
Hematological and renal toxicity according to CTCAE 5.0
Periodo de tiempo: From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Hematological and renal toxicity according to CTCAE 5.0 |
From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
Periodo de tiempo: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
Measured by SPECT/CT |
At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
Periodo de tiempo: Throughout the trial treatment phase (5 years)
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology |
Throughout the trial treatment phase (5 years)
|
|
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
Periodo de tiempo: At end of treatment, and 1 and 4 months after end of treatment.
|
Measured by SUVmax (maximum standardized uptake value) |
At end of treatment, and 1 and 4 months after end of treatment.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Silla de estudio: Jakob Stenman, MD PhD, Karolinska University Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores Neuroectodérmicos Primitivos Periféricos
- Tumores Neuroectodérmicos Primitivos
- Neuroblastoma
- Lutetium Lu 177 Dotatate
Otros números de identificación del estudio
Otros números de identificación del estudio
- LuDO-N
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .